Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: A retrospective analysis

Journal of Investigational Allergology and Clinical Immunology

Volumn 20, Issue 5, 2010, Pages 386-390

  Asero, R ^a   Tedesch, A ^b  

^a Ambulatorio di Allergologia   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Antihistamines; Chronic urticaria; Corticosteroids; Therapy

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DESLORATADINE; EBASTINE; LEVOCETIRIZINE; LORATADINE; NADROPARIN; PREDNISONE;

ADULT; AGED; ARTICLE; CHRONIC URTICARIA; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; EVENING DOSAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OUTCOME ASSESSMENT; PRESCRIPTION; REMISSION; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CLINICAL PROTOCOLS; DRUG RESISTANCE; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; URTICARIA;

EID: 78649366941     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PAJ, Nasser SM. BSACI Guidelines for the management of chronic urticaria and angioedema. Clin Exp Allergy 2007; 37: 631-50.
2. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136: 197-201.
3. Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, Braido F, Majani G, Canonica GW. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621-3.
4. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above licensed doses. Clin Exp Dermatol 2006; 32: 34-38.
5. Greaves MW. Chronic urticaria. New Engl J Med 1995; 332; 1767-72.
6. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664-72.
7. Grattan C, Powell S, Humphreys F. Management and diagnostic guidelines for urticaria and angio-edema. Br J Dermatol 2001; 144: 708-14.
8. Kaplan AP. Chronic urticaria: pathogenesis and treatment.J Allergy Clin Immunol 2004; 114: 465-74.
9. Kaplan AP. Urticaria and angioedema. In Adkinson NF, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER Eds. Allergy: Principles and practice. 6th ed. Mosby Inc. 2003; pp 1537-58.
10. Sabroe RA, Greaves MW. Chronic idiopathic urticaria with functional autoantibodies: 12 years on. Br J Dermatol 2006; 154: 813-9
11. Wedi B, Kapp A. Chronic urticaria: assessment of current treatment. Expert Rev Clin Immunol 2005; 1: 459-73.
12. Komarov HD, Metcalfe DD. Office-based management of urticaria. Am J Med 2008; 121: 379-84.
13. Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK, Gimenez-Arnau AM, Grattan CEH, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sanchez-Borges M, Schmid-Grendelmeier P, Schunemann H, Staubach P, Vena G, Wedi B EAACI/GA(2) LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-43.
14. Asero R, Tedeschi A, Cugno M. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated D-dimer: a pilot study. Int Arch Allergy Immunol 2010; 152: 384-9.
15. Asero R. Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing. Clin Exp Dermatol. 2005; 30: 582-3.
16. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005; 25: 451-68.
17. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 275: 71-8.
18. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4: 525-33.
19. Cohan VL, Undem BJ, Fox CC, Adkinson NF, Lichtenstein LM, Schleimer RP. Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin. Am Rev Respir Dis 1989; 140: 951-4.
20. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patents with chronic urticaria. Int Arch Allergy Immunol 2008; 148: 170-4.
21. Tedeschi A, Asero R, Marzano AV, Lorini M, Fanoni D, Berti E, Cugno M. Plasma levels and skin-eosinophil-expression of vascular endothelial growth factor in patients with chronic urticaria. Allergy 2009; 64: 1616-22.
22. Kita H, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ. Effect of steroids on the immunoglobulin-induced eosinophil degranulation. J Allergy Clin Immunol 1991; 87:70-7.
23. Schleimer RP, Lichtenstein LM, Gillespie E. Inhibition of basophil histamine release by anti-inflammatory steroids. Nature 1981; 292: 454-5.
24. Rhen T, Cidlowsky JA. Antiinflammatory action of glucocorticoids - New mechanisms for old drugs. N Engl J Med 2005; 353: 1711-23.